Boron therapeutics on the horizon.
Boron therapeutics on the horizon.
复制标题
DOI：
10.1097/00045391-200109000-00005
复制
发表时间：
2001-09-01
影响因子：
4.2
通讯作者：
Groziak, M P
中科院分区：
文献类型：
--
作者：
Groziak, M P
目前还没有基于硼的药物投放市场，但这种情况可能很快就会改变。新千年带来了一些独特的生物活性硼化合物，这些化合物在发展中已经足够成熟，被认为在各自的化疗领域取得了重大和及时的进展。由于硼很少被认为是生物活性物质的组成部分，本文综述了硼的一些相关的生物学和生理学性质，然后详细描述了那些在治疗视野中清晰可见的基于硼的试剂。重点介绍的药物包括有效的蛋白酶体抑制剂、β-内酰胺酶抑制剂、二肽基肽酶抑制剂、三磷酸肌醇受体调节剂、抗菌药物和抗雌激素。随着这些新药物被欢迎进入治疗性医疗机构，其他药物肯定会效仿，开处方的临床医生将已经意识到和欣赏这些化合物提供的独特好处。
No pharmaceutical based on boron has yet made it to market, but this may soon change. The new millennium has brought with it some unique classes of bioactive boron compounds that are sufficiently mature in development to be considered significant and timely advances in their respective chemotherapeutic areas. Because boron is seldom seen as a constituent of a bioactive agent, this review relates some of the pertinent biologic and physiologic properties of boron and then describes in detail those boron-based agents clearly visible on the therapeutic horizon. Highlighted agents include boronic acids and boron heterocycles as potent proteasome inhibitors, beta-lactamase inhibitors, dipeptidyl peptidase inhibitors, inositol trisphosphate receptor modulators, antibacterials, and antiestrogens. As these new agents are welcomed into the therapeutic armamentarium, others will surely follow and the prescribing clinician will already have an awareness and appreciation of the unique benefits that these compounds have to offer.